China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
HO
Press Releases
January 6, 2025

China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

- China has the highest number of cases and deaths from gastric cancer of any country worldwide1 -

bradford

The Bradford Era

Local & Social